Abstract YO16
Case summary
Thai male patient, 58 years old
He had been diagnosed essential hypertension and dyslipidemia for over 10 years (2005) and received cadaveric donor kidney transplantation on Oct 2005.
In May 2017, he presented with left hip closed fracture, in plain film of Lt hip had showed osteolytic lesion at left head and neck of femur with fracture at intertrochanter of femur.
He received bone biopsy and result showed metastatic clear cell renal cell carcinoma.
On CT chest and whole abdomen include pelvis had seen heterogeneous enhancing mass at right native kidney size 7.1 x 7.2 x 8.5 cm with synchronous lesion at transplanted kidney size 1.1 x 1.4 cm and pathological lymph nodes at internal iliac artery, no distance metastasis.
He underwent surgery to debulk tumor and hemiarthroplasty of left hip and received post-operative radiotherapy. Post-operative, he had been added everolimus 0.5 mg per day.
He starts treatment with Pazopanib since June 2007 until now and has hand foot syndrome grade I, diarrhea grade I, his blood pressure is well controlled and now he still has partial response.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract